Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06272942 · ClinicalTrials.gov registry record

An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States

A clinical trial of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS), sponsored by Bayer.

Active
Registry status
140,000
Enrollment target
1
Study location

NCT06272942: Active study of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS), sponsored by Bayer.

NCT06272942 is a study of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS) that is active but no longer recruiting, run by Bayer. The registered enrollment target is 140,000 participants, above the 235-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (59474% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06272942, a study of Acute Respiratory Distress Syndrome (ARDS) and Post Intensive Care Syndrome (PICS), is active but no longer recruiting, sponsored by Bayer.

ACTIVE NOT RECRUITING
Registry status
140,000 participants
Enrollment target
1
Study location

Study Summary

This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied. ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult. In observational studies, only observations are made without participants receiving any advice or any changes to health care. People who are admitted to ICU for serious illnesses, like ARDS, often experience new health problems during and after their ICU stays. These health problems that may include physical, mental, and/or emotional disorders, are called post-intensive care syndrome (PICS). Identifying these new health problems early can help people by timely treatments and care. In this study, researchers want to identify any health problems that arise after ICU admission in people with ARDS in the United States (US). To do this, researchers will collect information on health problems, treatments, medicines, and healthcare visits in people with ARDS, 1 year before and after an ICU admission. They will then look to see whether the health problems are in areas that have been described as the post intensive care syndrome (PICS). In addition, they will measure healthcare related costs in the one year after admission and compare it to the one year prior to admission. Researchers will also compare this information with data collected for people with pneumonia who did not require ICU admission. This will help them to identify any new health problems arising due to ICU stays. The data will come from participants' medical claims information stored in the Optum Clinformatics Data Mart database from 2016 to 2022. The claims data will only be collected for people in the US. Researchers will collect data from participants admitted to ICU for ARDS for a maximum of 1 year before and after their stay.

Primary Outcome

Morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.

Interventions

  • OTHER An ICU admission and a temporally related ARDS diagnosis

Study Locations (1)

New Jersey

  • Bayer - Whippany

Trial Details

FieldValue
Enrollment Target 140,000 participants
Start Date 2024-01-31
Est. Completion 2025-08-30
Bayer

591 total trials

What the registry record for NCT06272942 still lists

NCT06272942 is an observational study that tracks outcomes without assigning an intervention. Its 140,000 participants enrollment target places it among the larger protocols in the corpus, above the 235-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (59474% higher).

The record links to 2 conditions, with Acute Respiratory Distress Syndrome (ARDS) appearing as the primary indexed condition, and to 1 intervention - of which An ICU admission and a temporally related ARDS diagnosis is the first listed.

NCT06272942 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT06272942 about?

NCT06272942 is a clinical study titled "An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States". This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied. ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult. In observational s...

What is the current status of trial NCT06272942?

This trial is currently active not recruiting. The enrollment target is 140,000 participants. The study started on 2024-01-31. Estimated completion is 2025-08-30.

What conditions does trial NCT06272942 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS).

What interventions are being tested in trial NCT06272942?

The interventions under investigation include: An ICU admission and a temporally related ARDS diagnosis (OTHER).

Who is sponsoring clinical trial NCT06272942?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06272942 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Respiratory Distress Syndrome (ARDS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06272942's enrollment target sits among peer trials

140,000 1st of 8 higher than 8 of 8 other Acute Respiratory Distress Syndrome (ARDS) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome (ARDS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05994482 · 130,000 participants

    Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

  • NCT02693509 · 128,026 participants

    Get With The Guidelines-Heart Failure Registry

  • NCT06232551 · 152,000 participants · NA

    Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

  • NCT06917339 · 156,000 participants

    Retrospective Analyses of TrakStar Database

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06272942, the US trial registry maintained by the National Library of Medicine. NCT06272942 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.